Zealand Pharma Says Data From Part 1 Of Multiple Ascending Dose Trial With ZP8396 For Obesity Showed Mean Weight Loss Of 5.3%, 5.1% at 0.6, 1.2 mg doses Versus 2.6%, 3.6%, 4.2% at doses of 0.7, 1.4, 2.4 mg doses, Already Reported
Portfolio Pulse from Benzinga Newsdesk
Zealand Pharma has reported data from part 1 of its multiple ascending dose trial with ZP8396 for obesity. The results showed a mean weight loss of 5.3% and 5.1% at 0.6 and 1.2 mg doses respectively, compared to 2.6%, 3.6%, and 4.2% at doses of 0.7, 1.4, and 2.4 mg doses.
July 03, 2023 | 10:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive trial results for Zealand Pharma's ZP8396 for obesity could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up the stock price. Given that the results for ZP8396 were better than expected, this could potentially lead to a short-term increase in Zealand Pharma's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100